The National Institute of Neurological Disorders and Stroke (NINDS) has published the first detailed, high-resolution brain image from a person who suffered from chronic traumatic encephalopathy (CTE) or “CTE”.
The study is published in the Journal of Cerebral Blood Flow & Metabolism.
The National Institutes of Health (NIH) and the US Department of Veterans Affairs (VA) funded the study.
The study was carried out in conjunction with researchers from the University of Pennsylvania (UPA) and University of North Carolina (UNC).
The study found that a small subset of patients with CTE had abnormal connections between the temporal lobe and prefrontal cortex, which are areas associated with memory, reasoning and decision-making.
Researchers analysed the brain activity of these patients to see if their abnormal connections would impair memory.
They found evidence of abnormal connections in only 2% of patients.
Researchers also looked at whether the abnormal connections were associated with other areas of the brain that control brain function, including the cerebellum, which is responsible for movement and balance.
In the study, the scientists compared a patient’s abnormal connections with a group of healthy, healthy controls.
Researchers found that patients with abnormally-connected temporal lobe connections were more likely to be classified as having CTE.
This may be due to the abnormal connection between the brain and the temporal lobes that are connected by thinning and thinning of the cerebrum.
Researchers believe that abnormal connections to the temporal and prefrontal lobes are associated with CTCE, but this research is not definitive.
They also found that abnormal connectivity to the cerebri of the hippocampus, which controls memory, can also contribute to CTCEs.
The researchers say that this finding is important because it provides a direct link between the abnormal connectivity and the cognitive impairment that is associated with these disorders.
The findings highlight the importance of identifying and treating patients with a range of CTE symptoms before they develop CTE, and to develop therapies that are more effective at reducing cognitive impairment.